- Home
- CRBP vs WIMI Comparison
CRBP vs WIMI Comparison
Compare CRBP & WIMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBP
- WIMI
- Stock Information
- Founded
- CRBP 2009
- WIMI 2015
- Country
- CRBP United States
- WIMI China
- Employees
- CRBP N/A
- WIMI N/A
- Industry
- CRBP Biotechnology: Pharmaceutical Preparations
- WIMI Computer Software: Prepackaged Software
- Sector
- CRBP Health Care
- WIMI Technology
- Exchange
- CRBP Nasdaq
- WIMI Nasdaq
- Market Cap
- CRBP 103.6M
- WIMI 94.3M
- IPO Year
- CRBP N/A
- WIMI 2020
- Fundamental
- Price
- CRBP $8.18
- WIMI $1.27
- Analyst Decision
- CRBP Strong Buy
- WIMI
- Analyst Count
- CRBP 8
- WIMI 0
- Target Price
- CRBP $61.38
- WIMI N/A
- AVG Volume (30 Days)
- CRBP 291.7K
- WIMI 5.6M
- Earning Date
- CRBP 03-11-2025
- WIMI 01-01-0001
- Dividend Yield
- CRBP N/A
- WIMI N/A
- EPS Growth
- CRBP N/A
- WIMI N/A
- EPS
- CRBP N/A
- WIMI N/A
- Revenue
- CRBP N/A
- WIMI $84,137,968.00
- Revenue This Year
- CRBP N/A
- WIMI N/A
- Revenue Next Year
- CRBP N/A
- WIMI N/A
- P/E Ratio
- CRBP N/A
- WIMI N/A
- Revenue Growth
- CRBP N/A
- WIMI 19.25
- 52 Week Low
- CRBP $7.64
- WIMI $0.63
- 52 Week High
- CRBP $61.90
- WIMI $2.92
- Technical
- Relative Strength Index (RSI)
- CRBP 35.10
- WIMI 61.85
- Support Level
- CRBP $7.64
- WIMI $0.92
- Resistance Level
- CRBP $9.51
- WIMI $1.08
- Average True Range (ATR)
- CRBP 0.84
- WIMI 0.09
- MACD
- CRBP -0.05
- WIMI 0.04
- Stochastic Oscillator
- CRBP 13.71
- WIMI 73.35
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About WIMI WiMi Hologram Cloud Inc.
WiMi Hologram Cloud Inc and its subsidiaries offer augmented reality (AR) based holographic services and products to cater to its customers. Its AR service and product offerings primarily consist of holographic AR advertising services and holographic AR entertainment products. It is also into the semiconductor business, in which the company provides central processing algorithm services and computer chip products to enterprise customers and the sales of comprehensive solutions for central processing algorithms and related services with software and hardware integration. The company reports in three segments: AR advertising, AR entertainment, and Semiconductor. Its geographical segments are Mainland China, Hong Kong, and International.